These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 20007560)

  • 1. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.
    Hsieh MM; Kang EM; Fitzhugh CD; Link MB; Bolan CD; Kurlander R; Childs RW; Rodgers GP; Powell JD; Tisdale JF
    N Engl J Med; 2009 Dec; 361(24):2309-17. PubMed ID: 20007560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study.
    Dovern E; Aydin M; Hazenberg MD; Tang MW; Suijk EM; Hoogendoorn GM; Van Tuijn CFJ; Kerkhoffs JL; Rutten CE; Zeerleder SS; de la Fuente J; Biemond BJ; Nur E
    Am J Hematol; 2024 Aug; 99(8):1523-1531. PubMed ID: 38733340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.
    Saraf SL; Oh AL; Patel PR; Jalundhwala Y; Sweiss K; Koshy M; Campbell-Lee S; Gowhari M; Hassan J; Peace D; Quigley JG; Khan I; Molokie RE; Hsu LL; Mahmud N; Levinson DJ; Pickard AS; Garcia JG; Gordeuk VR; Rondelli D
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):441-8. PubMed ID: 26348889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem-cell transplantation for adults with sickle cell disease.
    Abboud MR
    N Engl J Med; 2009 Dec; 361(24):2380-1. PubMed ID: 20007564
    [No Abstract]   [Full Text] [Related]  

  • 6. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; Mackinnon S
    Blood; 2000 Oct; 96(7):2419-25. PubMed ID: 11001893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres.
    Alzahrani M; Damlaj M; Jeffries N; Alahmari B; Singh A; Rondelli D; Tisdale JF; Saraf SL; Hsieh MM
    Br J Haematol; 2021 Feb; 192(4):761-768. PubMed ID: 33534948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmyeloablative Matched Sibling Donor Hematopoietic Cell Transplantation in Children and Adolescents with Sickle Cell Disease.
    Guilcher GMT; Monagel DA; Nettel-Aguirre A; Truong TH; Desai SJ; Bruce A; Shah RM; Leaker MT; Lewis VA
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1179-1186. PubMed ID: 30772511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo immunological evaluation of stable mixed chimeric patients after matched related donor allogeneic transplantation in sickle cell disease.
    Raines LN; Hsieh MM; Nassehi T; Drysdale CM; Tisdale JF; Uchida N
    Cytotherapy; 2019 Dec; 21(12):1206-1215. PubMed ID: 31784240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.
    Rezvani AR; Storer BE; Guthrie KA; Schoch HG; Maloney DG; Sandmaier BM; Storb R
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):105-12. PubMed ID: 25278458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
    Iannone R; Casella JF; Fuchs EJ; Chen AR; Jones RJ; Woolfrey A; Amylon M; Sullivan KM; Storb RF; Walters MC
    Biol Blood Marrow Transplant; 2003 Aug; 9(8):519-28. PubMed ID: 12931121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
    Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation.
    Halaburda K; Marianska B; Warzocha K; Nasilowska-Adamska B; Szczepinski A; Tomaszewska A; Sawecka J; Skulimowska J
    Ann Transplant; 2009; 14(2):7-12. PubMed ID: 19487787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
    Chakraverty R; Peggs K; Chopra R; Milligan DW; Kottaridis PD; Verfuerth S; Geary J; Thuraisundaram D; Branson K; Chakrabarti S; Mahendra P; Craddock C; Parker A; Hunter A; Hale G; Waldmann H; Williams CD; Yong K; Linch DC; Goldstone AH; Mackinnon S
    Blood; 2002 Feb; 99(3):1071-8. PubMed ID: 11807015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.
    Dietz AC; Orchard PJ; Baker KS; Giller RH; Savage SA; Alter BP; Tolar J
    Bone Marrow Transplant; 2011 Jan; 46(1):98-104. PubMed ID: 20383216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
    Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
    Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.
    Horwitz ME; Barrett AJ; Brown MR; Carter CS; Childs R; Gallin JI; Holland SM; Linton GF; Miller JA; Leitman SF; Read EJ; Malech HL
    N Engl J Med; 2001 Mar; 344(12):881-8. PubMed ID: 11259721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor.
    Kawano Y; Takaue Y; Watanabe A; Takeda O; Arai K; Itoh E; Ohno Y; Teshima T; Harada M; Watanabe T; Okamoto Y; Abe T; Kajiume T; Matsushita T; Ikeda K; Endo M; Kuroda Y; Asano S; Tanosaki R; Yamaguchi K; Law P; McMannis JD
    Blood; 1998 Nov; 92(9):3123-30. PubMed ID: 9787147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.